{
  "docId": "019dd923-5f69-752d-a9b6-2758ff8024b8",
  "docSlug": "IOYPUci1JeH6qtF9hngI",
  "documentTitle": "See the 21-slide pitch deck a biotech startup used to convince investors like Pfizer to bet on fixing damaged organs",
  "authorId": "Pitchdecks",
  "authorName": "Agomab Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 9,
  "pageCount": 21,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-2758ff8024b8/9",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.21,
        "w": 0.94,
        "x": 0.03,
        "y": 0.233
      },
      "kind": "list",
      "text": "Advantageous drug properties: Oral, potent and GI-restricted small molecule inhibitor of ALK-5; Tissue restriction through rapid metabolization on first-pass in liver; Clean profile for hERG, cardiac ion channels and kinase panels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "269d4f3b-ae26-4ee9-80a3-2a1461ccf942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.94,
        "x": 0.03,
        "y": 0.438
      },
      "kind": "list",
      "text": "Well-characterized profile: Marked anti-fibrotic and anti-inflammatory efficacy in vitro, in vivo and ex vivo; Confirmed GI-restricted PK profile in mouse, rat, dog and human; Wide safety margins in GLP-tox studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75e250cb-cc0f-46eb-b106-62e740850f55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.94,
        "x": 0.03,
        "y": 0.643
      },
      "kind": "list",
      "text": "Development status: Ph1 SAD and food-interaction study finalized; Ph1 MAD ongoing; Ph1b in fibrostenotic Crohn’s disease patients to start early 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb462050-2c7f-4048-b5c9-76d6b964feea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.76,
        "x": 0.12,
        "y": 0.07
      },
      "kind": "title",
      "text": "AGMB-129: novel candidate for treatment of fibrostenotic CD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4c0ea70-ed28-40d9-a5e0-0c94e62a576c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "4d62e13c-3b16-456f-9fff-fc6382bb0de0",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "AGMB-129: novel candidate for treatment of fibrostenotic CD",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}